Treats insomnia characterized. ANDA 90107, held by Sandoz. Zolpidem Tartrate.
As of Nov 16, 2026, ANDA 90107 (Zolpidem Tartrate), held by Sandoz, was first approved by FDA on Jul 1, 2011, with 7 approved supplements and 0 published complete response letters.
1INDICATIONS AND USAGE Zolpidem tartrate extended-release tablet, USP is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance (as measured by wake time after sleep onset). The clinical trials performed in support of efficacy were up to 3 weeks (using polysomnography measurement up to 2 weeks in both adult and elderly patients) and 24 weeks (using patient-reported assessment in adult patients only) in duration. Zolpidem tartrate extended-release tablet, USP a gamma-aminobutyric acid (GABA) A agonist, is
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 1, 2011 | Original application | Approved | None posted |
| Zolpidem Tartrate6.25MG · tablet, extended release;oral | Zolpidem Tartrate | Rx |
| Zolpidem Tartrate12.5MG · tablet, extended release;oral | Zolpidem Tartrate | Rx |
| Nov 21, 2022 | Supplement 11Labeling · Standard review | Approved | None posted |
| Nov 19, 2019 | Supplement 6Labeling · Standard review | Approved | None posted |
| Nov 19, 2019 | Supplement 7Labeling · Standard review | Approved | None posted |
| Nov 19, 2019 | Supplement 8Labeling · Standard review | Approved | None posted |
| Nov 19, 2019 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jan 2, 2015 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jan 2, 2015 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jul 1, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters